Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.

Kountourakis P; Missitzis I; Doufexis D; Zobolas V; Pissakas G; Arnogiannaki N; Maliou S; Sotiropoulou A; Ardavanis A

首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.

【24h】

Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.

机译：新辅助序贯表柔比星和多西紫杉醇治疗，然后进行手术放疗和术后多西紫杉醇或吉西他滨/长春瑞滨联合治疗（基于主要反应）：针对局部晚期乳腺癌的多模式方法。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND: Locally advanced breast cancer (LABC) remains a major clinical issue despite progress achieved in recent years. Herein, we present the mature results of a multimodality treatment program tailoring epirubicin (EPI), docetaxel (DOC) and gemcitabine-vinorelbine (GEV) peri-operatively in LABC. PATIENTS AND METHODS: Stage III, Eastern Cooperative Oncology Group-Performance status

机译：背景：尽管近年来取得了进展，但是局部晚期乳腺癌（LABC）仍然是一个主要的临床问题。在此，我们介绍了LABC围手术期定制表柔比星（EPI），多西他赛（DOC）和吉西他滨-长春瑞滨（GEV）的多模式治疗方案的成熟结果。患者和方法：III期，东部合作肿瘤小组表现为

著录项

来源
《Journal of Cancer Research and Clinical Oncology》 |2011年第2期|共8页
作者
Kountourakis P; Missitzis I; Doufexis D; Zobolas V; Pissakas G; Arnogiannaki N; Maliou S; Sotiropoulou A; Ardavanis A;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer. [J] . Kountourakis P, Missitzis I, Doufexis D, Journal of Cancer Research and Clinical Oncology . 2011,第2期

机译：新辅助序贯表柔比星和多西紫杉醇治疗，然后进行手术放疗和术后多西紫杉醇或吉西他滨/长春瑞滨联合治疗（基于主要反应）：针对局部晚期乳腺癌的多模式方法。
2. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer. [J] . Yardley DA, Peacock NW, Dickson NR, Clinical breast cancer . 2010,第3期

机译：新辅助吉西他滨，表柔比星和多西他赛的II期试验作为局部晚期或炎症性乳腺癌患者的主要治疗方法。
3. The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer. [J] . Hirano A, Shimizu T, Imamura H, Anticancer Research: International Journal of Cancer Research and Treatment . 2006,第1B期

机译：Epirubicin Plus Docetaxel作为局部晚期乳腺癌的Neoadjuvant化疗的组合。
4. Functional Imaging of Neoadjuvant Chemotherapy Response in Women with Locally Advanced Breast Cancer using Diffuse Optical Spectroscopy [C] . Hany Soliman, Martin J. Yaffe, Gregory J. Czarnota Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2009

机译：弥漫光学光谱学局部晚期乳腺癌女性新辅助化疗反应的功能成像
5. Diffusion-weighted magnetic resonance imaging in monitoring treatment response in patients with locally advanced breast cancer. [D] . Singer, Lisa. 2010

机译：扩散加权磁共振成像可监测局部晚期乳腺癌患者的治疗反应。
6. HER-2 p53 p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination [O] . Daniel G Tiezzi, Jurandyr M Andrade, Alfredo Ribeiro-Silva, 2007

机译：新辅助多西紫杉醇联合表柔比星联合治疗局部晚期乳腺癌中HER-2p53p21和激素受体蛋白的表达是反应和预后的预测因素
7. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination [O] . Daniel G Tiezzi, Jurandyr M Andrade, Alfredo Ribeiro-Silva, 2007

机译：新辅助多西紫杉醇联合表柔比星联合治疗局部晚期乳腺癌中HER-2，p53，p21和激素受体蛋白的表达是反应和预后的预测因素

Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.

摘要

著录项

相似文献

相关主题

期刊订阅